Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 12;10:548300. doi: 10.3389/fonc.2020.548300

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Hu, An, Sun, Wang, Du, Li, Chi and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Identification of potential biomarkers associated with the efficacy of anlotinib. (A) OPLS-DA score plot of good and poor efficacy groups based on concentrations of all metabolites. (B) Random permutation test with 100 iterations. (C) PCA score plot of good and poor efficacy groups based on concentrations of the 12 metabolites with VIP > 1.5. (D) Compound names, VIP values, and FCs of the 12 metabolites with VIP > 1.5. (E) ROC and box plot of glycodeoxycholic acid. (F) ROC and box plot of glycocholic acid. (G) External validation of the OPLS-DA model. Samples in the discovery set were designed as good or poor groups, while samples in the validation set were designed as test-good or test-poor groups. Both depended on the best curative effect.